Unveiling Statins and Genetics in Age-Related Macular Degeneration: The Coimbra Eye Study—Report 9

• Published in: Investigative ophthalmology & visual science Vol. 65; no. 6; p. 38
• Main Authors: Barreto, Patrícia, Farinha, Cláudia, Coimbra, Rita, Cachulo, Maria Luz, Melo, Joana Barbosa, Lechanteur, Yara, Hoyng, Carel B., Cunha-Vaz, José, Silva, Rufino
• Format: Journal Article
• Language: English
• Published: United States The Association for Research in Vision and Ophthalmology 27.06.2024
• Subjects: Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Macular Degeneration - genetics; Male; Middle Aged; Polymorphism, Single Nucleotide; Retina; Risk Factors
• ISSN: 1552-5783; 0146-0404; 1552-5783
• DOI: 10.1167/iovs.65.6.38

To assess the association of age-related macular degeneration (AMD) progression and statins, connected with AMD genetic risk, and if there is an interplay between statins and genetics. In this analysis, 682 subjects made two visits (6.5-year follow-up) of the Coimbra Eye Study. Subjects who started taking statins at any time point between the two visits were considered. Progressors were defined as not having AMD at baseline and having any AMD at follow-up. Genetic risk scores (GRSs) were calculated individually with 52 independent variants associated with AMD. Time to progression was estimated using unadjusted Kaplan-Meier curves. An extended Cox model was used for the association between statins and GRS with the risk for AMD progression. Multiplicative and additive interactions were assessed. Median survival time was 7.50 years for subjects not taking statins and 7.62 for subjects taking statins (P < 0.001). Statin intake reduced the risk for progression to AMD in 48%, adjusting for age, sex, body mass index, smoking, and diabetes (model 1) and GRS (model 2). The combined effects of not taking statins and having high GRS increased the progression risk fourfold compared to taking statins and having low GRS (hazard ratio [HR] = 4.25; 95% confidence interval [CI], 1.62-11.16; P = 0.003). For subjects not taking statins, an increased risk of progression was found for those subjects with high GRS compared to subjects with low GRS (HR = 1.80; 95% CI, 1.13-2.85; P = 0.013). No statistically significant multiplicative or additive interactions were found. Statins seem to be protective against AMD progression, and genetics may play a role in treatment response.